This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correction

Since the initial publication of the review article [1], a number of readers have contacted us to clarify potential erroneous information
in the article. These comments focused on our review of the use of transcranial magnetic
stimulation (TMS) for treatment-resistant depression (TRD). In the initial article,
we concluded that TMS is well-tolerated and has been approved by the FDA for adults
who have failed to respond to one antidepressant, but that its use in TRD was not
yet supported by rigorous double-blind randomized clinical trials. It should be noted,
that for the article, we searched PubMed and based our review on the several meta-analyses
we found during this search.

1. The NIH-sponsored large multicenter trial [2] was published in 2010, not 2009. Also, note that the primary outcome measure of this
study was remission, not response (as was the case in the Neuronetics study [3]). Most important, we erroneously reported that most remitters had low antidepressant
resistance. In fact, the relationship between remission and treatment resistance was
not significant. Also, the study cohort had an average of 1.5 failed research-quality
adequate treatment trials (by Antidepressant Treatment History Form [ATHF] criteria),
which translates approximately to 3 to 6 clinical medication trials, in the current
episode and an average of 3.3 failed research-quality adequate treatment trials (approximately
9 clinical attempts) during their lifetimes. In conclusion, the data from George et
al. [2] support the efficacy of TMS for TRD.